Drug development
The development of biotechnologically produced drugs has made it possible to treat diseases at their cause, to do this more efficiently and with fewer side effects, or even to cure diseases. This is the focus of five biotechnology companies on Campus Berlin-Buch.
The spectrum of their drug development includes highly specific cancer antibodies (Glycotope GmbH), novel treatments targeting the cause of heart failure (Berlin Cures GmbH) or atrial fibrillation (OMEICOS Therapeutics GmbH), extremely effective antibiotics (MerLion Pharmaceuticals) and RNAi-based therapeutics for systemic cancers that can selectively regulate disease-related genes (Silence Therapeutics). Here, T-Knife, a spin-off from the Charité and the Max Delbrück Center, is developing one of the first T cell receptor gene therapies in Germany.
News innovation
From cell biology to CRISPR/Cas – new knowledge for schools
The Life Science Learning Lab at the Berlin-Buch research campus offers both school students and teachers the opportunity to immerse themselves in science. This year, the facility celebrates its 25th ...
more ...Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
Eckert & Ziegler BEBIG GmbH, subsidiary of Eckert & Ziegler SE with focus on brachytherapy solutions for the treatment of prostate cancer as well as eye and brain tumors, obtained the MDR certificate ...
more ...Eckert & Ziegler Completes Change of Legal Form to SE
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today completed its change of legal form to a Societas Europaea (SE) with entry in the company's commercial register and will in fu...
more ...Events Campus
06.05.2024, 09:00
Realtime PCR und digital PCR Kurs
Der RealTime PCR und Digital PCR Kurs richtet sich an erfahrene PCR Anwender*innen und an Einsteiger*innen. Wichtige PCR Grundlagen werden erörtert, bevor die RealTime PCR besprochen und Genexpression...
more ...22.06.2024, 16:00
Lange Nacht der Wissenschaften 2024
Save the date!
more ...
